Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupICD10C49.-MeSHHemangiosarcomaRhabdomyosarcoma, EmbryonalSequencePAED Soft Tissue Sarcoma, "Non-RMS-like"-tumors (NRSTS) in the High Risk GroupPAED Soft Tissue Sarcoma, CWS-PROPOSAL FOR ANGIOSARCOMAPAED Soft Tissue Sarcoma, Localised "RMS-like" tumours (SySa, STET (EES, pPNET), UDS)PAED Soft Tissue Sarcoma, Primary metastatic soft tissue tumoursPAED Soft Tissue Sarcoma, RMS Low Risk Group - Subgroup APAED Soft Tissue Sarcoma, RMS Standard Risk Group - Subgroup BPAED Soft Tissue Sarcoma, RMS Very High Risk Group- Subgroup HPAED Soft Tissue Sarcoma, second line therapy according to CWS-2002-P (TECC)PAED Soft Tissue Sarcoma, second line therapy ACCTTIVEPAED Soft Tissue Sarcoma, second line therapy CWS-91-REZPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup CPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup D, E, F, GVAIA III, Soft Tissue SarcomaChemotherapyChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineNo. Substances123 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimNo. Substances12458Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseTherapy intentioncurativepalliativeRisksEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeutropeniaOral Mucositis only studiesPublicationAuthorKoscielniak E, Klingebiel TTreuner J. Koscielniak EDiseaseWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneOriginCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceProtocols in Revision 25 protocols foundProtocols under revision.PAED CWS-Guidance, ACCTTIVE - Vincristine 1.5 / Doxorubicin 20 / Cyclophosphamide 1200, Soft Tissue Sarcoma (PID1311)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1296)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Soft Tissue Sarcoma (PID1297)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1293)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1294)PAED CWS-Guidance, CEVAIE, I³VE - Ifosfamide 3 / Vincristine 1.5 / Etoposide 150, Soft Tissue Sarcoma (PID1298)PAED CWS-Guidance, CWS-91-REZ, Block A - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1305)PAED CWS-Guidance, CWS-91-REZ, Block B- Ifosfamide 2 / Etoposide 150, Soft Tissue Sarcoma (PID1306)PAED CWS-Guidance, CWS-91-REZ, Block C - Carboplatin 150 / Ifosfamide 2, Soft Tissue Sarcoma (PID1307)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, VNCR intensification, Soft Tissue Sarcoma (PID1287)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1288)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Vincristine intensification, Soft Tissue Sarcoma (PID1290)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Soft Tissue Sarcoma (PID1292)PAED CWS-Guidance, O-TE - Trofosfamide 75 / Etoposide 25, Soft Tissue Sarcoma, maintenance (PID1304)PAED CWS-Guidance, O-TI - Trofosfamide 75 / Idarubicin 5, Soft Tissue Sarcoma, Maintenance (PID1303)PAED CWS-Guidance, Paclitaxel 200, Angiosarcoma (PID1320)PAED CWS-Guidance, TECC Block A / ACCTTIVE - Topotecan 1 / Carboplatin 150, Soft Tissue Sarcoma (PID1308)PAED CWS-Guidance, TECC Block B - Topotecan 1 / Cyclophosphamide 250, Soft Tissue Sarcoma (PID1309)PAED CWS-Guidance, TECC Block C / ACCTTIVE - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1310)PAED CWS-Guidance, VA - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1237)PAED CWS-Guidance, VA2 - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1289)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661)